Mantle Cell Lymphoma BGB 11417-201 

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Bcl-2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma.

Description

Mantle Cell Lymphoma BGB 11417-201 consists of two parts. Part 1 determines the safety and tolerability of BGB-11417 monotherapy, the maximum tolerated dose, and the recommended Phase 2 dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the recommended Phase 2 dose with recommended ramp-up schedule from Part 1.

Sponsor: BeiGene

Principal Investigator: Dr. Tara Graff

Email Us About This Trial

Back To Clinical Trials NCI Database Entry